This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Addressing Unmet Medical Needs for Patients with COPD-CHEST

Addressing Unmet Medical Needs for Patients with COPD-CHEST

Format

Webcast

Time to Complete

1.50 hours

Released

December 31, 2018

Expires

December 31, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditTM
1.50 / CE for Nurses (0.70 pharmacotherapy credit)

Joint Providers

Jointly provided by Postgraduate Institute for Medicine (PIM) and ASiM.

Commercial Supporter

Supported by an independent educational grant provided by GlaxoSmithKline

Program Description

Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease. Management of patients with COPD has been complicated by newly approved guidelines that incorporate novel escalation strategies with dual bronchodilation treatments. Fixed dose combination (FDC) dual bronchodilation, consisting of a long-acting ß agonist (LABA) combined with a long-acting muscarinic antagonist (LAMA), has emerged as an effective strategy for patients who require escalation beyond LABA or LAMA monotherapy. For patients who require escalation beyond LAMA/LABA or other dual therapies, the FDA recently approved the first, and currently only, fixed-dose, once-daily triple therapy (LAMA/LABA/inhaled corticosteroid [ICS]) inhaler. Despite updated recommendations, there is limited practical guidance for individualizing therapy or identifying patients who may benefit from treatment escalation (ie, escalating from mono- to dual bronchodilation therapy or adding an ICS/escalating to triple therapy). In addition, lack of knowledge of appropriate COPD inhaler use and self-management strategies persist among patients/caregivers, precluding optimal therapeutic benefit and clinical outcomes. This archived symposium activity will feature 3 international experts in COPD, who will review and discuss the clinical science behind dual bronchodilation therapy, advances in triple therapy, and the new COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.

Intended Audience

This educational initiative is designed for physicians, physician assistants, nurse practitioners, and nurses engaged in the care of patients with COPD in pulmonology settings.

Educational Objectives

After completing this activity, the participant should be better able to:

  • EVALUATE scientific evidence supporting the use of dual bronchodilation and triple drug therapy to improve lung function, manage symptoms, and reduce exacerbations in COPD.
  • UTILIZE the most up-to-date COPD guidelines on treatment initiation and escalation strategies that include dual bronchodilation and ICS.
  • EMPLOY strategies that provide disease education and inhaler training to patients with COPD.
  • DEVELOP individualized COPD maintenance treatment strategies, considering patient-specific appropriate use of dual bronchodilation and ICS therapies.

Conflict Of Interest Disclosure Policy

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

James F. Donohue, MD (Chair)
Professor of Medicine and Former Chief
of the Division of Pulmonary and
Critical Care Medicine
University of North Carolina at Chapel
Hill School of Medicine
Chapel Hill, North Carolina

Dr. Donohue discloses the following:
Consulting fees: AstraZeneca, GlaxoSmithKline, and Mylan

MeiLan K. Han, MD
Professor
Internal Medicine
Division of Pulmonary and Critical Care Medicine
Director, Michigan Airways Program
University of Michigan Health System
Ann Arbor, Michigan

Dr. Han discloses the following:
Consulting fees: AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline
Other non-financial support: Novartis and Sunovion

Nicola Alexander Hanania, MD, MS, FCCP, FERS
Associate Professor
Section of Pulmonary and
Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Houston, Texas

Dr. Hanania discloses the following:
Consulting fees: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi-Regeneron, and Sunovion Pharmaceuticals Inc.
Contracted Research: GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim

PLANNERS AND MANAGERS DISCLOSURES

The PIM planners and managers have nothing to disclose.
The ASiM CE LLC planners and managers have nothing to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.50

Type

CE for Nurses

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.50 contact hours. Designated for 0.50 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions

There are no fees for participating and receiving CME or CNE credit for this activity. During the period December 31, 2018 through December 31, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

To obtain credit a score of 75% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue